Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Treatment of ocular inflammatory diseases using laquinimod

a technology of ocular inflammatory diseases and laquinimod, which is applied in the direction of biocide, immunological disorders, drug compositions, etc., can solve problems such as permanent vision loss, and achieve the effect of high oral bioavailability

Inactive Publication Date: 2013-12-05
TEVA PHARMA IND LTD
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a new treatment for ocular inflammatory diseases, such as uveitis and conjunctivitis, using a drug called laquinimod. This drug has been tested in humans for multiple sclerosis and has shown promising results in treating these eye conditions. The patent describes a method of treatment involving frequent use of laquinimod or its salt for a limited period of time. The patent also provides pharmaceutical compositions containing laquinimod for use in the treatment of various types of ocular inflammation. Overall, this patent provides a novel and effective treatment option for ocular inflammatory diseases.

Problems solved by technology

Inflammation from uveitis may result in a variety of other eye conditions, including glaucoma, cataracts, and cystoid macular edema, and ultimately may lead to permanent vision loss.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

experimental examples

Example 1

Evaluation of Efficacy Following Daily Topical Administration of Laquinimod In S-Antigen-Induced Experimental Autoimmune Uveitis in Rats (EAU Model)

[0068]General.

[0069]A 1% (10 mg / ml) and a 5% (50 mg / ml) solution of laquinimod sodium were prepared in sterile water. Dissolution of laquinimod powder was achieved by shaking, stirring, or low-speed vortex. The solutions were stored for up to 2 weeks at 2-8° C. and up to 24 hours at room temperature. Laquinimod solutions were prepared under light protection and were protected from light for the duration of the experiment. Cyclosporine A was used as a reference material at a concentration of 25 mg / kg / j (Fluka). One 100 mg / 4 ml in olive oil dose was prepared every 2 days and stored at room temperature.

[0070]Animals and Animal Husbandry.

[0071]Thirty two (32) female albino Lewis rats, approximately 8 weeks old, were used for this study. All rats were held in observation for at least 3 days to monitor for signs of ill health or ocula...

example 2

Evaluation of Ocular Active Anaphylaxis Reduction Following Topical Ocular Administration Of Laquinimod in Mice (Late Phase) Using Ovalbumin Model

[0085]General.

[0086]Laquinimod solutions were prepared as in Example 1.

[0087]Animals and Animal Husbandry.

[0088]Forty (40) male Balb / c albino mice were used for this experiment. The mice were about 7-8 weeks old upon ordering, and were held in observation for at least three (3) days to monitor for signs of ill health or ocular abnormalities. Only healthy animals were accepted for use in this study. The rats were housed under identical environmental conditions, with a relative humidity of 55%±10%, continuous ventilation, and an automatic 12 hour light / dark cycle. Environmental conditions were continuously controlled and recorded. Animals had free access to food and water.

[0089]Materials and Methods.

[0090]Forty (40) Balb / c albino mice were randomly allocated to five groups of eight animals each. Only the right eyes of each animal were used i...

example 3

Dose Conversion Between Species

[0109]The National Institutes of Health (NIH) provides a table of Equivalent Surface Area Dosage Conversion Factors below (Table 8) which provides conversion factors that account for surface area to weight ratios between species.

TABLE 8Equivalent Surface Area Dosage Conversion FactorsToMouseMonkey20 gRat 150 g3 kgDog 8 kgMan 60 kgFROMMouse1½¼⅙  1 / 12Rat21½¼ 1 / 7Monkey421⅗⅓Dog641⅔1½Man127321

[0110]In the examples 4-9 below, the administration of the composition is once daily. The administration can be repeated daily for a period of one, two, three or four days, up to 14 days, or longer as necessary.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to View More

Abstract

Disclosed is a method for treating an ocular inflammatory disease (OID), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an OID, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway. This application also provides a method for treating a subject suffering from an autoimmune disease-associated ocular inflammation comprising periodic ocular administration to the subject a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt, and an ocular pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating an autoimmune disease-associated ocular inflammation.

Description

[0001]This application claims benefit of U.S. Provisional Application No. 61 / 655,526, filed Jun. 5, 2012, the entire content of which is hereby incorporated by reference herein.[0002]Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.BACKGROUND OF THE INVENTION[0003]Ocular Inflammatory Disease (“OID”) is a general term for describing inflammation affecting one or more parts of the eye or surrounding eye tissue. Uveitis is the inflammation of the uvea or the uveal tract, which includes the iris, the ciliary body and the choroid portions of the eye. Inflammation of the overlying retina, called retinitis, or of the optic nerve, called optic neuritis, may occur with or without accompanying uveitis. Anatomically, uveitis may be classified as anterior, intermediate, posterio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K31/4704
CPCA61K9/0048A61K31/4704A61P27/02A61P27/14A61P29/00A61P37/06A61P37/08A61K9/0053A61K9/08
Inventor KAYE, JOELHALLAK, HUSSEINTARCIC, NORA
Owner TEVA PHARMA IND LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com